CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
64.45
-4.19 (-6.10%)
Mar 18, 2026, 4:00 PM EDT - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
The 11 analysts that cover CG Oncology stock have a consensus rating of "Strong Buy" and an average price target of $71.27, which forecasts a 10.58% increase in the stock price over the next year. The lowest target is $47 and the highest is $90.
Price Target: $71.27 (+10.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 5 | 5 | 5 |
| Buy | 6 | 5 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 12 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $80 | Strong Buy | Maintains | $75 → $80 | +24.13% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $66 → $75 | Strong Buy | Maintains | $66 → $75 | +16.37% | Feb 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $61 → $73 | Buy | Maintains | $61 → $73 | +13.27% | Jan 21, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $55 → $70 | Buy | Maintains | $55 → $70 | +8.61% | Jan 16, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $62 → $66 | Strong Buy | Maintains | $62 → $66 | +2.40% | Jan 12, 2026 |
Financial Forecast
Revenue This Year
24.32M
from 4.04M
Increased by 501.93%
Revenue Next Year
141.36M
from 24.32M
Increased by 481.30%
EPS This Year
-2.51
from -2.08
EPS Next Year
-2.11
from -2.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 116.5M | 441.9M | |||
| Avg | 24.3M | 141.4M | |||
| Low | n/a | 24.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2,783.7% | 1,717.1% | |||
| Avg | 501.9% | 481.3% | |||
| Low | - | 0.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.43 | -0.24 | |||
| Avg | -2.51 | -2.11 | |||
| Low | -3.26 | -2.92 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.